Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors
DOI:
https://doi.org/10.1002/edn.221Keywords:
incretin hormones, GLP-1, DPP-4, treatment, type 2 diabetesAbstract
AbstractIncretin therapy is a glucose-lowering therapy which has attracted great interest during recent years. It is based on the antidiabetic action of the incretin hormone glucagon-like peptide-1 (GLP-1), which involves both stimulation of insulin secretion and inhibition of glucagon secretion. This results in lowering of both fasting and postprandial glycaemia. Incretin therapy is either with GLP-1 receptor agonists or with inhibitors of dipeptidyl peptidase-4 (DPP-4), which is the enzyme which inactivates endogenous GLP-1. The GLP-1 receptor agonists are injected subcutaneously once or twice daily or once weekly. The DPP-4 inhibitors are oral tablets taken once or twice daily. Both therapies reduce HbA1c without weight gain, and for GLP-1 receptor agonists with a weight reduction. Incretin therapy is safe with very few adverse events and an additional value of the therapy is a very low risk for hypoglycaemia. Incretin therapy is efficient both in monotherapy and in combination with metformin, sulphonylureas, thiazolidinediones and insulin. Its main indication is as add-on to metformin in patients who are insufficiently controlled on metformin alone, and an important indication is also in combination with insulin therapy. The experienced value of incretin therapy for patient care will most likely result in increased use of this therapy during the coming years.
Downloads
References
Drucker DJ, Nauck MA. The incretin sys-tem: glucagon-like peptide-1 receptor ago-nists and dipeptidyl peptidase4 inhibitors in type 2 diabetes. Lancet 2006;368: 1696–705.
Dunning BE, et al. Alpha-cell function in health and disease: influence of GLP-1. Diabetologia 2005;48:1700–13.
Nauck MA, et al. Glucagon-like peptide-1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997;273(5 Pt 1):E981–8.
Gutzwiller JP, et al. Glucagon-like peptide-1promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999;276:R1541–4.
Ahrén B. GLP-1 for type 2 diabetes. Exp Cell Res 2011;317:1239–45.
Gutniak M, et al. Antidiabetic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992;326:1316–22.
Zander M, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic con-trol, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824–30.
Deacon CF, et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2 terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44:1125–31.
Ahrén B. GLP-1-based therapy of type 2 dia-betes: GLP-1 mimetics and DPP-W inhibitors. Curr Diabet Rep 2007;7:340–7.
Meier JJ. GLP-1 receptor agonists for individ-ualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;109:728–42.
Scott LJ. Exenatide extended-release: a review of its use in type 2 diabetes mellitus. Drugs 2012;72:1679–707.
Keta R, Davies MJ. Treatment evaluation of liraglutide in type 2 diabetes. Exp Opin Biol Ther 2012;12:1551–6.
Drucker DJ, et al. Exenatide once weekly ver-sus twice daily for the treatment of type 2 diabetes: a randomized, open-label, non-inferiority study. Lancet 2008;372:1240–50.
Buse JB, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a ran-domised, open-label study. Lancet 2013;381: 117–24.
Fineman MS, et aL GLP-1 based therapies: dif-ferential effects on fasting and postprandial glucose. Diabetes Obes Metab 2012;14:675–88.
Ahrén B, et al. Inhibition of dipeptidyl pepti-dase IV improves metabolic control over a 4 week study period in type 2 diabetes. Diabetes Care 2002;25:869–75.
Deacon CF. Dipeptidyl peptidase4 inhibitors in the treatment of type 2 diabetes: a com-parative review. Diabetes Obes Metab 2011; 13:7–18.
Ahrén B. Use of DPP4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes Obes Metab 2010;3:31–41.
Ahrén B. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin - diabetes control and poten-tial adverse events. Best Pract Res Chn Endocrinol Metab 2009;23:487–98.
Deeks ED. Linagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2012;762:1793–824.
Deacon CF, et al. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl pepddase4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes: a review and meta-analysis. Diabetes Obes Metab 2012;14:762–7.
Barnett AH, et al. Key considerations around the risks and consequences of hypogly-caemia in people with type 2 diabetes. Int J Chn Pract 2010;64:1121–9.
Desouza CV, et al. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010; 33:1389–94.
Zoungas S, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010;363:1410–8.
DeFronzo RA, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092–100.
Nauck M, et al. Efficacy and safety compari-son of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84–90.
Charbonnel B, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inad-equately controlled with metformin alone. Diabetes Care 2006;29:2638–43.
Bosi E, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30: 890–5.
DeFronzo RA, et al. The efficacy and safety of saxagliptin when added to metformin ther-apy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649–55.
Taskinen MR, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a random-ized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011;13:65–74.
Ahrén B, et al. Vildaglipdn enhances islet responsiveness to both hyper- and hypo-glycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009;94:1236–43.
Dore DD, et al. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25: 1019–27.
Drucker DJ, et al. The safety of incretin-based therapies - review of the scientific evidence. J Clin Endocrinol Metab 201196: 2027–31.
Stratton IM, et al. Association of glycaemia with macrovascular and microvascular com-plications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405–12.
Usscher JR, Drucker DJ. Cardiovascular biol-ogy of the incretin system. Endocr Rev 2012;33:187–215.
Mannucci E, Dicembrini I. Incredn-based therapies and cardiovascular risk. Curr Med Res Opin 2012;28:715–21.
Lorber D. GLP- J receptor agonists: effects on cardiovascular risk reduction. Cardiovasc Ther 2012 Jul 30. doi: 10.1111/cdr.12000. [Epub ahead of print.]
Monami M, et al. Dipeptidyl peptidase4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013;15:112–20.
Ahrén B. Are sulfonylureas less desirable than DPP-4 inhibitors as add-on to met-formin in the treatment of type 2 diabetes? Curr Diabet Rep 2011;11:83–90.
Ferrannini E, et al. Fifty-two week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009;11: 157–66.
Fonseca V, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50:1148–55.
Vilsboll T, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:167–77.
Balena R, et al. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab 2012 Oct 15. doi: 10.1111/dom.12025. [Epub ahead of print.]
Berlie H, et al. Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a sys-tematic review. Diabetes Metab Syndr Obes 2012;5:165–74.
Barnett A, et al.. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Cuff Med Res Opin 2012;28: 513–23.
Inzucchi SE, et al. Management of hypergly-caemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55: 1577–96.
Paolisso G, et al. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks? Adv Ther 2012;29: 218–33.
Mathieu C, Bollaerts K. Andhyperglycaemic therapy in elderly patients with type 2 dia-betes: potential role of incretin mimetics and DPP-4 inhibitors. Int J Clin Pract 2007;154:29–37.
Sisson EM. Liraglutide: clinical pharmacol-ogy and considerations for therapy. Pharmacother 2011;31:896–911.
Scheen AJ. DPP4 inhibitors in the manage-ment of type 2 diabetes: a critical review of head-to-head studies. Diabetes Metab 2012; 38:89–101.
Gantz I, et al. Effect of MK-3102, a novel once-weekly DPP-4 inhibitor, over 12 weeks in patients with type 2 diabetes mellitus. Diabetologia 2012;55 (Suppl 1):551.
Issa CM, Azar ST. Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus. Curr Diab Rep 2012;12: 560–7.
Farngren J, et al. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypo-glycemia in type 1 diabetes. J Clin Endocrinol Metab 2012;97:3799–806.
Astrup A, et al. Effects of liraglutide in the treatment of obesity: a randomized, double-blind, placebo-controlled study. Lancet 2009; 374:1606–16.
Harkavyui A, Whitton PS. Glucagon-like peptide 1 receptor stimulation as a means of neuroprotecdon. Br J Pharmacol 2010;159: 495–501.
Drucker DJ, Rosen CE Glucagon-like pep-tide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology. Diabetologia 2011;54:2471–4.
Ahrén B. The incretin-based therapy: novel avenues - novel targets. Diabetes Obes Metab 2011;13(Suppl 1):158–66.
Bergenstal RM, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431–9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2013 Copyright © 2013 FEND.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
